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Anaplasma marginale Major Surface Protein 2 CD4-T-Cell Epitopes
Are Evenly Distributed in Conserved and Hypervariable
Regions (HVR), Whereas Linear B-Cell Epitopes
Are Predominantly Located in the HVR
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Organisms in the genus Anaplasma express an immunodominant major surface protein 2 (MSP2), composed
of a central hypervariable region (HVR) flanked by highly conserved regions. Throughout Anaplasma marginale
infection, recombination results in the sequential appearance of novel MSP2 variants and subsequent control
of rickettsemia by the immune response, leading to persistent infection. To determine whether immune evasion
and selection for variant organisms is associated with a predominant response against HVR epitopes, T-cell
and linear B-cell epitopes were localized by measuring peripheral blood gamma interferon-secreting cells,
proliferation, and antibody binding to 27 overlapping peptides spanning MSP2 in 16 cattle. Similar numbers
of MSP2-specific CD4 T-cell epitopes eliciting responses of similar magnitude were found in conserved and
hypervariable regions. T-cell epitope clusters recognized by the majority of animals were identified in the HVR
(amino acids [aa] 171 to 229) and conserved regions (aa 101 to 170 and 272 to 361). In contrast, linear B-cell
epitopes were concentrated in the HVR, residing within hydrophilic sequences. The pattern of recognition of
epitope clusters by T cells and of HVR epitopes by B cells is consistent with the influence of protein structure
on epitope recognition.
Tick-borne pathogens in the family Anaplasmataceae infect
and persist in reservoir mammalian hosts, with acute disease
occurring after transmission to a naïve host. Acute infection is
characterized by high-level rickettsemia resulting in clinical
disease, whereas persistent infection is typified by recurrent
low-level, subclinical rickettsemic peaks (10, 13, 17). Common
to the pathogens in the genera Anaplasma and Ehrlichia are
immunodominant outer membrane proteins (OMP) with de-
fined conserved and variable domains (13, 15, 21, 23, 26, 30). In
Anaplasma spp., gene conversion of msp2 pseudogenes into a
single expression site provides an efficient mechanism to gen-
erate the large number of OMP variants seen during persistent
infection (1, 2, 4, 12). Novel Anaplasma marginale MSP2 vari-
ants arise in sequential rickettsemic peaks, followed by clear-
ance that is associated with generation of primary immuno-
globulin G (IgG) antibody responses against variant-specific
B-cell epitopes localized to the central hypervariable region
(HVR) (12, 13). More recently, epitopes that elicited high
levels of gamma interferon (IFN-) production by CD4 T
cells were identified in conserved and variable domains of
A. marginale MSP2 (6, 7). The induction and recall of T-cell
responses, including production of IFN- for macrophage ac-
tivation and provision of help for antibody production, in par-
ticular IgG2, are proposed to be required for control of emer-
gent variants (7, 25). The importance of CD4 T cells and
IFN- in controlling infection with other Ehrlichia spp. has also
been reported (3, 14, 20).
Detailed knowledge of the epitope specificity of T- and B-
lymphocyte responses to conserved and variable domains of
A. marginale MSP2 is necessary to understand the selection for
variants during infection. If the majority of IFN--secreting
CD4 T lymphocytes were specific for HVR epitopes, control
of emergent variants would require primary T-lymphocyte re-
sponses in addition to primary B-lymphocyte responses di-
rected against variable region epitopes. Such predominant rec-
ognition of variable epitopes could facilitate immune evasion
and persistent infection. Previous studies that identified T-cell
epitopes in conserved and hypervariable regions of MSP2 were
performed with proliferation assays using T-cell lines that were
cultured for several weeks and obtained from only three ani-
mals (6, 7). Responses by in vitro propagated cell lines derived
from few animals might be biased towards recognition of a few
immunodominant epitopes. To more comprehensively test the
hypothesis that the majority of T- and B-lymphocyte epitopes
reside within the HVR, the present study used peripheral
blood mononuclear cells (PBMC), rather than T-cell lines,
from 16 outbred cattle immunized with MSP2. The animals
expressed 10 different major histocompatibility complex
(MHC) class II DRB3 alleles and 11 different combinations of
DRB3 alleles. Furthermore, the present study measured the
number of peptide-specific IFN--secreting cells by enzyme-
linked immunospot (ELISPOT) assay in addition to levels of
proliferation and IFN- secretion. The strengths of this ap-
proach are that the ELISPOT assay specifically quantifies
those IFN--producing T lymphocytes that are important for
the control of anaplasmosis and that the use of three T-cell
assays may reveal a greater number of epitopes, as demon-
strated by a study examining epitope recognition by PBMC
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from humans exposed to malaria (11). To determine B-cell
epitopes on MSP2, immune sera from the MSP2-immunized
animals were also used to identify peptides by enzyme-linked
immunosorbent assay (ELISA).
All cattle were previously immunized (29) with gel-purified
MSP2 (22, 28). Twenty animals were allocated into five groups
with four calves per group. Groups I to IV were immunized six
times with 50 g of MSP2 adsorbed in 2 mg of alum (29). The
cattle received no additional adjuvant (group I) or the follow-
ing: 1 mg of control non-CpG oligodeoxynucleotide (ODN)
R2006 (group II), 1 mg of CpG ODN 2006 (group III), or 10
g of recombinant human interleukin-12 (IL-12) (group IV).
Calves in group V served as a control group and received alum
plus CpG ODN 2006 but no MSP2. The Kyte and Doolittle
method (18) was used to generate a hydropathic profile of
MSP2 (Fig. 1). Imbricated 24- to 30-mer peptides that overlap
by 10 to 20 amino acids and span the Florida strain MSP2 A
variant sequence derived from msp2 clone 1-7 (GenBank ac-
cession no. AY138954) were synthesized (6, 7) and used for T-
and B-cell epitope mapping. The MSP2 A variant was the most
common variant transcript identified in the blood utilized for
MSP2 immunization (6). The relative positions of the MSP2
peptides are shown in Fig. 1.
Five to six months after immunization, 0.5  106 PBMC
were assayed for IFN- production by ELISPOT assay (29).
When PBMC from all animals were stimulated with a mixture
of phytohemagglutinin (PHA; 1.0 g per ml), IL-12 (0.01 ng
per ml), and IL-18 (0.5 ng per ml), which served as a positive
control for IFN- synthesis (27, 29), large numbers of IFN--
producing cells were detected, achieving or nearing saturation
of the test wells. Antigens consisted of 10 and 1 g of unin-
fected bovine erythrocyte membranes (URBC) per ml, A. mar-
ginale Florida strain homogenate, native MSP2, or MSP2-de-
rived peptides diluted in complete RPMI 1640 medium (11)
(Table 1). Significant responses to A. marginale antigen were
seen in 73% of the MSP2-vaccinated animals (11 of 16), and
50% (8 of 16) of vaccinated animals had significant responses
to MSP2 (Table 1). Four age-matched steers that were used as
controls and given adjuvant without MSP2 responded signifi-
cantly to PHA, IL-12, and IL-18 but not to A. marginale or
MSP2 (data not shown).
We next verified that the A. marginale-specific IFN--secret-
ing cells are predominantly CD4 T lymphocytes by depleting
specific cell subsets with monoclonal antibody (MAb) obtained
from the Washington State University Monoclonal Antibody
Center. Depletion of CD4 T lymphocytes to 1% of total
cells with CD4-specific MAb ILA-11A bound to magnetic
beads (16) significantly reduced the number of lymphocytes
responding to either A. marginale (P  0.01) or MSP2 (P 
0.01) to numbers similar to background numbers from lym-
phocytes stimulated with medium alone or URBC (Fig. 2). In
contrast, bead depletion of CD8 T lymphocytes by using
MAb 7C2B and of  T lymphocytes by using MAb GB21A to
1% of the total cells did not significantly reduce the response.
This finding is consistent with our previous results from using
CD4 T clones to detect responses to MSP2-derived peptides,
where peptide-specific T cells produced IFN-, which was
measured by ELISA, and responses were blocked by anti-
MHC class II-specific antibody (6–8).
To test the hypothesis that the CD4 T-cell response is
predominantly directed to the HVR of MSP2, IFN- ELI-
SPOT responses to conserved and hypervariable region pep-
tides (Fig. 1) were evaluated and compared. The data in Table
1 are representative of independent experiments performed
two or three times. When responses from all 16 vaccinated
animals were considered together, 47% of the significant pep-
tide-specific responses (52 of 110 responses) were directed at
peptides from the conserved N- and C-terminal regions, and
53% (58 of 110 responses) were directed at HVR peptides.
One-way analysis of variance with Bonferroni’s correction re-
vealed no significant differences in the magnitude of the re-
sponses to the conserved or hypervariable region peptides
when the data for individuals or all 16 animals together were
analyzed. Importantly, the equivalent distribution of T-cell epi-
topes in the conserved and hypervariable regions of MSP2 was
observed regardless of the level of immunity achieved by ad-
ministering a given adjuvant.
The ELISPOT analysis revealed that peptides that were
recognized by the largest number of animals were from the
HVR (Table 1). Peptides HV4 and HV5 were each recognized
by PBMC from 10 of 16 vaccinated animals, and peptide HV3
was recognized by 7 of 16 vaccinated animals. In addition,
peptides HV4 and HV5 stimulated one of the three strongest
T-cell responses in 6 of the 10 responders. The HVR of MSP2
has been shown to undergo sequential, segmental gene con-
version during A. marginale infection within specifically defined
areas of change identified as blocks 1, 2, and 3 (5). These
regions are proposed to be important for immune evasion and
persistent infection, as changes in T-lymphocyte epitopes
within blocks 1 and 2 resulted in significantly reduced T-lym-
phocyte recognition (6). Thus, peptides HV2 to HV5 spanning
amino acids (aa) 171 to 229 constitute an epitope cluster in this
important region of the protein shown to undergo sequential,
segmental gene conversion in vivo.
During persistent infection, memory T-cell responses to con-
FIG. 1. Hydropathic profile of full-length A. marginale MSP2. The
central hypervariable region, aa 190 to 272, which represents the MSP2
A variant from the Florida strain (6), is predominantly hydrophilic and
identified by shading. Amino acid position is indicated on the x axis,
and the hydropathy index, representing the average value over a win-
dow of 19 amino acids, is indicated on the y axis. The overlapping
peptides are represented under the hydropathic profile as black bars in
groups of five to illustrate the relative position in the whole protein.
The numbering of the amino acids corresponds to the msp2 11.2
genomic DNA clone (24).
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served epitopes could activate macrophages and B cells to
rapidly generate a protective response and thus provide a
means to control the level of rickettsemia and ultimately clin-
ical disease during persistence (7). We found that segments of
both N- and C-terminal conserved regions of MSP2 also elic-
ited strong IFN--secreting CD4 T-lymphocyte responses.
Conserved region peptides P7 and P10, which most commonly
elicited significant responses, were each recognized by PBMC
from 8 of 16 vaccinated animals. Peptide P13 was recognized
by PBMC from 7 of the 16 vaccinated animals. As for HVR
peptides, commonly recognized peptides P7 and P13 stimu-
lated one of the three strongest T-lymphocyte responses. One
or more of peptides P6 to P8 were recognized by 10 of 16
animals, indicating that aa 101 to 170 constitute an epitope
cluster in the N-terminal region. A second conserved epitope
cluster in MSP2 was found in the C terminus at aa 272 to 361,
as one or more of the peptides P10 to P13 were recognized by
14 of 16 vaccinated animals.
To verify the results obtained with the IFN- ELISPOT
assay, proliferation assays and IFN- ELISAs were performed
simultaneously using the same samples of PBMC and antigens.
In addition, it was possible that certain peptide-specific T lym-
phocytes did not produce IFN- and these responses would be
missed by the ELISPOT assay. Proliferation assays were car-
ried out in replicate wells of round-bottomed 96-well plates for
6 days, essentially as described previously (7, 9). When prolif-
eration was measured, 49.5% of the significant peptide-specific
responses (57 of 115 responses) were directed at peptides from
the conserved N- and C-terminal regions, and 50.4% of these
(58 of 115 responses) were directed at peptides spanning the
HVR (Table 2). The data in Table 2 are representative of
results from independent experiments performed two or three
times. IFN- ELISA also showed that IFN- responses di-
rected at conserved and hypervariable region peptides were
not significantly different (data not shown). Thus, these two
assays confirmed the results from ELISPOT and also showed
that the CD4 T-cell response was evenly divided between
hypervariable and conserved regions. The correlation of pep-
tide-specific responses determined by ELISPOT assay with
those determined by proliferation assay or ELISA for each
individual and by adjuvant groups was determined by using
multivariate linear regression and Pearson’s correlation. Inter-
estingly, in cattle with strong responses, such as those in the
IL-12 group, there was a significant correlation in recognition
of peptides with IFN- ELISPOT and proliferation assays (r2
ranged from 0.64 to 0.79 for individuals) or IFN- ELISPOT
and IFN- ELISA (r2 ranged from 0.68 to 0.85 for individuals).
However, in animals with weaker responses, the correlation
between assays was less significant (data not shown) and sim-
ilar to that reported for humans exposed to malaria (11).
To map linear IgG epitopes on MSP2, sera were obtained 2
weeks following the last immunization. Immulon II 96-well
ELISA plates were coated with 1 g of antigen or overlapping
peptides spanning MSP2 per well. Responses were considered
positive if the mean optical density at 450 nm (OD450) of
duplicate samples was3 times the mean OD450 to peptide P2,
which has repeatedly yielded results similar to those from me-
dium alone in the IgG ELISA. Immune sera from all animals
bound significantly to whole MSP2 (Table 3). As hypothesized,
72% of the peptides that were recognized significantly by sera
from all animals are located in the HVR. The most commonly
recognized peptides from the HVR include peptides HV3 (13
of 16 animals); HV2, HV6, and HV7 (12 of 16 animals); HV5
and HV11 (9 of 16 animals); and HV4 and HV10 (8 of 16
animals). The most commonly recognized peptides from the
conserved region include peptides P9 (15 of 16 animals) and P4
and P8 (9 of 16 animals).
Evasion of immunity to A. marginale is believed to result, at
least in part, from antigenic variation in the central HVR of
MSP2 (6, 12, 23, 25). Because antigenic variation can lead to
loss of both T- and B-lymphocyte recognition (6, 12), this study
hypothesized that MSP2-specific T- and B-cell responses
would be directed predominantly against epitopes within the
HVR, which could foster organism persistence. To test the
hypothesis, T-cell responses to MSP2 epitopes were deter-
mined by using PBMC, rather than cultured T-cell lines, from
16 animals expressing a broad repertoire of MHC class II
molecules and by performing three separate assays to detect
the largest number of potential epitopes. Our results showed
that there was no significant difference in the number of T-cell
FIG. 2. Identification of T-lymphocyte subsets that secrete IFN- detected by ELISPOT assay. PBMC from MSP2-alum-CpG ODN-immunized
animals no. 87 (panel A) and no. 78 (panel B), untreated and after depletion of either CD4 cells or CD8 cells and  T cells, were tested by
an IFN- ELISPOT assay. The results are presented as the mean number of spot-forming cells (SFC) plus 1 standard deviation per 106 PBMC
cultured with 10 g of antigen per ml after subtracting the mean number of SFC in cells cultured with medium.
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stimulatory peptides in conserved and hypervariable regions of
MSP2 or in the strength of the T-lymphocyte responses to
peptides from conserved or hypervariable regions, and our first
hypothesis is rejected. However, in accordance with our second
hypothesis, the majority of peptides recognized by immune
sera are located within the HVR. This serologic immunodomi-
nance of the MSP2 HVR supports the importance of antigenic
variation in maintaining persistent infection. Furthermore, the
preferential recognition of HVR B-cell epitopes is consistent
with this hydrophilic region being surface exposed (24). Simi-
larly, studies with related Ehrlichia chaffeensis showed that the
amino-terminal hypervariable region of OMP-1 was also im-
munodominant for mice and humans and contained linear
B-cell epitopes (19).
T cells from the majority of MSP2-immunized cattle recog-
nized two T-lymphocyte epitope clusters within the conserved
regions. Furthermore, one of these (aa 272 to 361, represented
by peptides P10 to P13) is completely conserved in another
antigenically variant surface protein, MSP3 (1, 4, 12). Thus,
these immunodominant, conserved sequences could be impor-
tant for providing accelerated memory T-cell responses during
persistent infection with organisms that continually undergo
variation in MSP2 and MSP3 (1, 4, 12). Although these results
were obtained following immunization with MSP2 rather than
infection with A. marginale, the recognition by T cells of de-
fined epitope clusters in MSP2 and the preferential recognition
by B cells of hydrophilic, variable region epitopes, regardless of
the magnitude of the individual MSP2-specific responses, are
consistent with protein structure influencing the pattern of
epitope recognition.
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